High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbCellera Biologics Inc (ABCL) progresses its lead program into Phase II, despite reporting a net loss and increased R&D expenses.
AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued preparation for multiple clinical catalysts expected over the next two years. President and CEO Dr. Carl
Tryn Stimart: Thank you for joining us for AbCellera Biologics Inc.'s First Quarter 2026 Earnings Call. Doctor Carl L. Hansen, AbCellera Biologics Inc.'s President and CEO, Doctor Sarah Noonberg, AbCellera Biologics Inc.'s Chief Medical Officer, and Andrew Booth, AbCellera Biologics Inc.'s Chief Financial Officer, are speaking on today's call.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.